CRD 740
Alternative Names: CRD-740Latest Information Update: 16 May 2024
At a glance
- Originator Cardurion Pharmaceuticals
- Class Cardiovascular therapies; Heart failure therapies
- Mechanism of Action Phosphodiesterase 9A inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Cardiovascular disorders; Heart failure
Most Recent Events
- 11 May 2024 Efficacy and adverse event data from the phase II CARDINAL-HF trial in Cardiovascular disorders released by Cardurion Pharmaceuticals
- 07 Nov 2023 Cardurion Pharmaceuticals terminated Phase-II clinical trials in Cardiovascular disorders in Israel, Canada, United Kingdom, USA (PO) (NCT05409183)
- 07 Nov 2023 Cardurion Pharmaceuticals terminated Phase-II clinical trials in Heart failure in Israel, Canada, United Kingdom, USA (PO) (NCT05409183)